Company intelligence / Profile preview

NeuromaxBionevia

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

BNV-222, an extended-release formulation of diepalrestat (a cocrystal of epalrestat and a reversible aldose reductase inhibitor), was in a Phase 2b randomized, double-blind, placebo-controlled study in Russia for diabetic peripheral neuropathy. The trial enrolled 400 subjects across 27 sites. The drug aims to be the first disease-modifying therapy for diabetic neuropathy by inhibiting aldose reductase and preventing nerve/tissue damage from excess glucose. Results were anticipated to support regulatory filings in Russia and potentially the US pending positive outcomes[1][2].

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

BioNevia LLCMaxwell Biotech Venture Fund

Beyond the preview

Go deeper on NeuromaxBionevia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuromaxBionevia.

Explore the full profile